| scholarly article | Q13442814 |
| P2093 | author name string | Hattori T | |
| Kido H | |||
| Koito A | |||
| Katunuma N | |||
| Takatsuki K | |||
| P2860 | cites work | Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS) | Q22242256 |
| The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus | Q28259668 | ||
| Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor | Q28646793 | ||
| T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV | Q28646817 | ||
| Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120 | Q33571605 | ||
| Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees | Q33582665 | ||
| Chymotrypsin- and trypsin-type serine proteases in rat mast cells: properties and functions | Q34193785 | ||
| Biological functions of serine proteases in mast cells in allergic inflammation | Q38200153 | ||
| pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane | Q41764642 | ||
| Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus | Q41876028 | ||
| HIV infection does not require endocytosis of its receptor, CD4. | Q45149382 | ||
| Antibodies to papain. A selective fractionation according to inhibitory capacity | Q70080789 | ||
| P433 | issue | 1-2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 48-52 | |
| P577 | publication date | 1989-05-01 | |
| P1433 | published in | FEBS Letters | Q1388051 |
| P1476 | title | Involvement of tryptase-related cellular protease(s) in human immunodeficiency virus type 1 infection | |
| P478 | volume | 248 |
| Q59070021 | A chink in HIV's armour? |
| Q36295519 | A complementarity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro |
| Q35864006 | A role for urokinase-type plasminogen activator in human immunodeficiency virus type 1 infection of macrophages. |
| Q68046962 | A sequence related to the human gonadoliberin precursor near the N-termini of HIV and SIV gag polyproteins |
| Q36633911 | Alteration of V3 loop context within the envelope of human immunodeficiency virus type 1 enhances neutralization |
| Q36656386 | Analysis of mutations in the V3 domain of gp160 that affect fusion and infectivity |
| Q59049332 | Anti-HIV drug mechanism |
| Q28325705 | Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease |
| Q41852319 | Characteristics of the Principal Neutralizing Determinant of HIV-1 Prevalent in Japan |
| Q39609216 | Characterization of V3 Loop-Binding Protein(s) of Molt-4 and U937 Cells |
| Q40066675 | Complementation of murine cells for human immunodeficiency virus envelope/CD4-mediated fusion in human/murine heterokaryons |
| Q44210464 | Computer predictions of functional, topogenic, and antigenic domains in human immunodeficiency virus-2 envelope glycoprotein |
| Q36797568 | Conformational features of a synthetic cyclic peptide corresponding to the complete V3 loop of the RF HIV-1 strain in water and water/trifluoroethanol solutions. |
| Q72693466 | Conformational rearrangements required of the V3 loop of HIV-1 gp120 for proteolytic cleavage and infection |
| Q40059624 | Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions |
| Q36672092 | Discovery and in vitro development of AIDS antiviral drugs as biopharmaceuticals |
| Q37783033 | Early events of HIV infection as targets for antiviral agents |
| Q33684772 | Endogenous salivary inhibitors of human immunodeficiency virus |
| Q36630413 | Enhanced in vitro human immunodeficiency virus type 1 replication in B cells expressing surface antibody to the TM Env protein. |
| Q45869482 | Expression of human CD4 in transgenic mice does not confer sensitivity to human immunodeficiency virus infection |
| Q36636241 | Factors involved in entry of the human immunodeficiency virus type 1 into permissive cells: lack of evidence of a role for CD26. |
| Q52216971 | Global and local structural properties of the principal neutralizing determinant of the HIV-1 envelope protein gp120. |
| Q36708990 | HIV-neutralizing antibodies: epitope identification and significance for future vaccine |
| Q36828914 | Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120 |
| Q40308952 | Human immunodeficiency virus type 1 entry into T cells: more-rapid escape from an anti-V3 loop than from an antireceptor antibody |
| Q33720162 | Human immunodeficiency virus type 1 envelope glycoprotein molecules containing membrane fusion-impairing mutations in the V3 region efficiently undergo soluble CD4-stimulated gp120 release |
| Q36645175 | Human immunodeficiency virus type 1 envelope gp120 is cleaved after incubation with recombinant soluble CD4 |
| Q40567149 | Human immunodeficiency virus type 1-associated CD4 downmodulation. |
| Q41979990 | Identification of Conserved Residues in the Human Immunodeficiency Virus Type 1 Principal Neutralizing Determinant That Are Involved in Fusion |
| Q37476959 | Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes |
| Q36820658 | Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages |
| Q24315636 | Identification of the U-937 membrane-associated proteinase interacting with the V3 loop of HIV-1 gp120 as cathepsin G |
| Q36687883 | Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain |
| Q45056043 | Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3 |
| Q43745920 | Increased mast cell density during the infection with velogenic Newcastle disease virus in chickens |
| Q42276973 | Inhibition of U‐937 membrane‐associated cathepsin G by GP 120 (IIIB) and V3 loop‐derived peptides from several strains of HIV‐1 |
| Q28368050 | Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120 |
| Q41100854 | Inhibition of human immunodeficiency virus type 1 infection in a T-cell line (CEM) by new dipeptidyl-peptidase IV (CD26) inhibitors |
| Q62022354 | Inhibitory effect of the oral immune response modifier, bestatin, on cell-mediated and cell-free HIV infection in vitro |
| Q41573921 | Interaction between a membrane-associated serine proteinase of U-937 monocytes and peptides from the V3 loop of the human immunodeficiency virus type 1 (HIV-1) gp120 envelope glycoprotein |
| Q41711801 | Intracellular signalling mediating HIV-1 gp120 neurotoxicity. |
| Q39457849 | Isolation and characterization of human immunodeficiency virus type 1 variants infectious to brain-derived cells: detection of common point mutations in the V3 region of the env gene of the variants. |
| Q36685201 | Macrophage-tropic human immunodeficiency virus isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: definition of critical amino acids involved in cell tropism |
| Q36702147 | Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins |
| Q35837553 | Mediation of human immunodeficiency virus type 1 binding by interaction of cell surface heparan sulfate proteoglycans with the V3 region of envelope gp120-gp41. |
| Q41381188 | Multibranched peptide constructs derived from the V3 loop of envelope glycoprotein gp120 inhibit human immunodeficiency virus type 1 infection through interaction with CD4. |
| Q40308489 | Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization |
| Q73402698 | NMR study of the peptide present in the principal neutralizing determinant (PND) of HIV-1 envelope glycoprotein gp120 |
| Q24634681 | Pathogenesis of human immunodeficiency virus infection |
| Q27733366 | Perturbations in the surface structure of A22 Iraq foot-and-mouth disease virus accompanying coupled changes in host cell specificity and antigenicity |
| Q36697652 | Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule |
| Q35832208 | Proteinase-resistant factors in human erythrocyte membranes mediate CD4-dependent fusion with cells expressing human immunodeficiency virus type 1 envelope glycoproteins |
| Q42550973 | Pseudopeptide TASP inhibitors of HIV entry bind specifically to a 95-kDa cell surface protein. |
| Q62009584 | Pseudoproline: Induktion einer biologisch relevantencis-Peptidbindung in Mimetika der V3-Schleife des HIV-1-Proteins gp120 |
| Q36889165 | Replication of patient isolates of human immunodeficiency virus type 1 in T cells: a spectrum of rates and efficiencies of entry |
| Q39318713 | Role of cell surface glycosaminoglycans of human T cells in human immunodeficiency virus type-1 (HIV-1) infection |
| Q28293679 | Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro |
| Q41547625 | Separation and partial characterization of proteinases with substrate specificity for basic amino acids from human MOLT-4 T lymphocytes: identification of those inhibited by variable-loop-V3 peptides of HIV-1 (human immunodeficiency virus-1) envelop |
| Q38890604 | Sequence Analysis of the V3 Loop Regions of theenvGenes of Ugandan Human Immunodeficiency Proviruses |
| Q36720405 | Serpin A1 and CD91 as host instruments against HIV-1 infection: are extracellular antiviral peptides acting as intracellular messengers? |
| Q42276430 | Single Basic Amino Acid Substitutions at Position 302 or 320 in the V3 Domain of HIV Type 1 Are Not Sufficient to Alter the Antiviral Activity of Dextran Sulfate and Heparin |
| Q37239053 | Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1 |
| Q41690309 | Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by simian immunodeficiency virus |
| Q41628089 | Sulfated polysaccharides extracted from sea algae as potential antiviral drugs |
| Q28324011 | Synergistic combinations and peptides in the inhibition of human immunodeficiency virus |
| Q38359834 | T-cell membrane-associated serine protease, tryptase TL2, binds human immunodeficiency virus type 1 gp120 and cleaves the third-variable-domain loop of gp120. Neutralizing antibodies of human immunodeficiency virus type 1 inhibit cleavage of gp120. |
| Q34738486 | The anti-HIV-1 activity associated with saliva |
| Q74248184 | The binding of a glycoprotein 120 V3 loop peptide to HIV-1 neutralizing antibodies. Structural implications |
| Q27729741 | The complete Consensus V3 loop peptide of the envelope protein gp120 of HIV-1 shows pronounced helical character in solution |
| Q36669879 | The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. |
| Q40049070 | The region of the envelope gene of human immunodeficiency virus type 1 responsible for determination of cell tropism |
| Q45864641 | The vaccinia virus K2L gene encodes a serine protease inhibitor which inhibits cell-cell fusion |
| Q42547004 | Triazine dyes inhibit HIV-1 entry by binding to envelope glycoproteins |
| Q55241764 | Tryptase TL2in the membrane of human T4+lymphocytes is a novel binding protein of the V3 domain of HIV-1 envelope glycoprotein gp120 |
| Q73815978 | Unexpected molecular mimicry among peptides MHC class II, blood-clotting factor X, and HIV-1 envelope glycoprotein GP120 |
| Q37870902 | Use of mandelic acid condensation polymer (SAMMA), a new antimicrobial contraceptive agent, for vaginal prophylaxis |
Search more.